such as steatohepatitis and hereditary hemochromatosis. Clinicians can then make best use of the information derived from the liver biopsy to help them advise patients on the natural history of ...

Nonalcoholic steatohepatitis (NASH ... The presence of inflammation on liver biopsy is associated with the development of advanced fibrosis in NASH. The presence of acinar inflammation is ...

"The drug is a targeted therapy that directly addresses the metabolic dysfunction in the liver in patients with metabolic dysfunction-associated steatohepatitis ... have a liver biopsy showing ...

Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solution ...

The lack of a liver biopsy requirement “removes a potential ... Some specialists have begun calling it metabolic dysfunction-associated steatohepatitis, or MASH, to avoid potentially ...

The study enrolled 888 patients who had metabolic risk factors and a baseline or recent liver biopsy showing MASH ... of patients with resolution of steatohepatitis (defined as a score of 0 ...

in patients with biopsy-confirmed compensated cirrhosis (F4), Child-Pugh Class A, due to metabolic dysfunction-associated steatohepatitis (MASH). Among patients with baseline and week 96 biopsies ...

"Patients with metabolic-associated steatohepatitis (MASH) also showed higher LDH levels. LDH levels were positively linked ...

Akero Therapeutics, Inc. (NASDAQ:AKRO) released preliminary topline week 96 results from SYMMETRY Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin (EFX) in ...